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Unique  human  T  cell  surface  antigens  have  been  used  to  distinguish  T 
lymphocytes from other hematopoietic cells. Some of these antigens have been 
used to analyze and separate human T  cells into functional subsets (1-5). 
Human  T  cells can  be  divided into two major subsets according to the cell 
surface phenotypes. Thus, the helper/inducer T  cells are Leu-1 ÷, Leu-2-, Leu- 
3 ÷, and Leu-4  ÷ (T1 +, T4 ÷, T8-, and T3+), whereas the cytotoxic/suppressor T 
cells are  Leu-1 +, Leu-2  ÷,  Leu-3-, and Leu-4  + (T1 +, T4-,  T8 ÷, and T3 +) (2-7). 
Recent  studies  of cloned  T  cells  have  suggested  that  some  of these  surface 
antigens might play a role in T  cell function (8-10). 
Monoclonal  antibodies  directed  against  these  antigens  are  being  tested  as 
therapeutic agents for the treatment of T  cell malignancies and immunoregula- 
tory diseases (1 1-15).  One problem  that can  reduce  the effectiveness of such 
treatment is the release of free antigen.  In our experience, free Leu-1  antigen 
appeared  in  the  serum  of patients  after  they  received  monoclonal  antibody 
infusions (1 1).  These observations  suggest that T  cell  surface antigens can  be 
released into serum under certain circumstances. 
In this report we describe the development of sensitive enzyme-linked immu- 
noassays for the detection of soluble Leu-1, -2, and -3 antigens. We also describe 
the physiological release of the Leu-2 antigen from Leu-2-bearing cells. 
Materials and Methods 
Monoclonal Antibodies.  The production and characterization of mouse monoclonal anti- 
Leu-1  antibody (clone L17F12) have been previously described (1). Mouse monoclonal 
anti-Leu-2a,  anti-Leu-3a,  and  anti-Leu-3b  have  been  characterized  in  detail  (2,  16). 
Purified preparations of these antibodies and their biotinated derivatives were obtained 
from Becton, Dickinson & Co., Mountain View, CA. 
Preparation of Rabbit Anti-Leu Sera.  Leu-1 and Leu-2 antigens were purified by absorp- 
tion onto affinity columns. Img of purified monoclonal antibody was coupled to ~ 1 ml 
of packed volume of Sepharose  4B  beads (Pharmacia,  Uppsala,  Sweden) activated by 
cyanogen bromide (17).  A cell  lysate from  10 ~  human thymocytes in a  lysis buffer of 
0.5%  Nonidet P-40  (NP-40) ~ (BDH  Chemicals Ltd., Poole, United Kingdom), 50 mM 
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Tris, 5 mM EDTA,  1 mM phenylmethylsulfonyl fluoride (Sigma Chemical Co., St. Louis, 
MO) and 1 ug pepstatin A (Sigma Chemical Co.), pH 7.6, was applied first to an anti-Leu- 
1 and subsequently to an anti-Leu-2a column. After washing the columns extensively with 
0.5%  NP-40  in  phosphate-buffered  saline (PBS),  the  beads were  mixed with complete 
Freund's adjuvant and used directly for immunization.  1/8 of the beads were injected in 
rabbits subcutaneously three times at 2-wk intervals.  1 wk after the last immunization, 
rabbits were  bled and  the  sera were  collected and  heat  inactivated.  Rabbit anti-Leu-1 
serum (RL-1) and rabbit anti-Leu-2 serum (RL-2) were passed over their respective mouse 
monoclonal antibody columns to absorb anti-mouse immunoglobulin activity before their 
use in immunoassay. 
Enzyme-linked Immunosorbent  Assays (ELISA) for the Detection of Soluble Leu-1  and Leu-2 
Antigens.  Each well of a 96-well Immulon plate (Dynatech Laboratories, Inc., Alexandria, 
VA) was coated with 50 #l of purified anti-Leu- 1 or anti-Leu-2a antibody at a concentration 
of 10 #g/ml in PBS, the plates were incubated overnight at 4°C, and then washed three 
times with  PBS.  To  block free binding sites, the  plates were  covered with  1%  bovine 
serum  albumin  (BSA) (fraction V,  Miles Laboratories Inc.,  Elkhart,  IN)  and  PBS  and 
incubated for  1 h  at room temperature.  The plates were then washed three times with 
0.05%  NP-40  and  PBS  (washing  buffer).  Then  50  #1  of sample  (cell  lysate,  culture 
supernatant, or serum) was added to a  well and a  twofold dilution was made with 0.1% 
NP-40, 2% BSA, 0.05% NAN3, and PBS (dilution buffer). After incubating for 2 h at 4°C, 
the plates were washed extensively with washing buffer. Then,  50 #1 of RL-1 or RL-2 in 
dilution buffer was put into the appropriate wells. After incubating 2 h at 4 °C and washing 
again extensively, 50 #1 of 1:1,500 diluted horseradish peroxidase (HRP)-conjugated goat 
anti-rabbit IgG (Tago Inc.,  Burlingame,  CA) in  0.1%  NP-40,  2%  BSA, and  PBS were 
added to each well. The plates were incubated for 1 h at room temperature and washed 
again in the same manner. Finally, 100 ~1 of substrate, 2,2'-azino-di(3-ethylbenzthiazoline 
sulfonic acid-6) ammonium salt (Sigma Chemical Co.), at a concentration of 150 #g/ml in 
0.05  M  citric acid, pH 4.0, with 0.01%  H~O~, was added to each well. After incubating 
for 30 rain at room temperature in the dark, the absorbance at 405 nm of each well was 
determined by ELISA reader (Dynatech Laboratories, Inc.). 
Assay  for Leu-3 Antigen.  The procedures were similar to Leu- 1 and Leu-2 ELISA except 
that anti-Leu-3b was used to coat the plate and 50 #1 of 1 #g/ml biotinated anti-Leu-3a 
in dilution buffer was used as the detector. After incubating for 2 h at 4°C, the plate was 
washed extensively with washing buffer and  50 #1 of HRP-conjugated avidin-D (Vector 
Laboratories, Burlingame, CA) diluted 1:1,500  in 0.1%  NP-40, 2%  BSA, and PBS were 
added to each well. The plate was incubated for 20 min at room temperature and washed. 
The final steps were done in the same manner as in Leu-I and Leu-2 ELISA. 
Cell Culture.  The human cell lines used in this study and their phenotypes are listed 
in Table I. Cell line 255.88, a gift of Dr. E. Engleman, Department of Pathology, Stanford 
TABLE  I 
Phenotvpe of Cell Lines 
Leu-1  Leu-2a  Leu-3a  Leu-4 
HPB-ALL  +  +  +  + 
JM  +  +  +  + 
MOLT-4  +  +  +  + 
HSB-2  +  -  -  - 
84O2  +  -  -  - 
255.88  +  -  +  + 
Jurkat  +  -  -  + 
8866  .... 
SB  .... 
Raji  .... 
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University, is a T-T hybridoma made with human peripheral T  cells and an azaserine- 
hypoxanthine-sensitive variant  derived  from  the Jurkat  cell  line  (18).  All  cells  were 
maintained in RPMI  1640 supplemented with 15% fetal calf serum (FCS) and antibiotics 
at 37°C in a 5% CO2 atmosphere. 
Preparation of Cell Lysates.  Cultured cells (5 x  107) were washed twice with PBS and 
were lysed for 1 h on ice with 1 ml of lysis buffer. Nuclei were removed by centrifugation 
at 5,000 g for 10 rain. Cell lysates were then centrifuged at 25,000 g for 1 h and they 
were kept frozen at -20°C until use. 
Preparation of Culture Supernatants.  Culture supernatants of cell lines were collected 
when cell numbers in culture were  ~  1 x  106/ml.  Sodium azide was added to a  final 
concentration of 0.05%. In a time course experiment, cell numbers were adjusted to 2.5 
x  105/ml and the cells were cultured in the presence or absence of FCS at 37°C in a 5% 
CO~ atmosphere. Cell numbers and cell viability were determined every 24 h by trypan 
blue dye exclusion. 
Preparation of Human  Sera.  Sera from healthy donors and from leukemia patients, 
including three cases of T  cell acute lymphoblastic leukemia (T-ALL) and two cases of B 
cell chronic lymphocytic leukemia (B-CLL), were collected and kept frozen at -70°C. 
Immunoprecipitation and Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS- 
PAGE).  HPB-ALL cells,  1 x  107, were labeled with 1 mCi of 12~I by the lactoperoxidase 
method (19).  Cell lysates were prepared in  1 ml of lysis buffer as described above. The 
affinity-purified Leu-2 antigen  (1  x  107 cell equivalents) from culture supernatant of 
HPB-ALL cells was radioiodinated by the chloramine-T method and radiolabeled protein 
was separated by Sephadex G25 sizing column (Pharmacia).  10 ul of rabbit serum or 10 
~g of mouse monoclonal antibody was incubated with 100 #1 of radioactive cell iysate or 
radioiodinated  purified  Leu-2  antigen  (500,000  cpm),  and  immune  complexes were 
precipitated with  either  150  #1  of 10%  heat-fixed Staphylococcus aureus Cowan  I  (The 
Enzyme Center, Boston, MA) for rabbit serum, or 150 ILl of goat anti-mouse IgG (Tago 
Inc.) for mouse monoclonal antibody. Immunoprecipitated materials were analyzed by 
SDS-PAGE under reducing or nonreducing conditions (20). 
Results 
Characterization  of Rabbit Anti-Leu-1  and Anti-Leu-2 Antisera.  The rabbit anti- 
sera were compared with monoclonal antibodies in their ability to recognize their 
homologous cell surface antigens. Immunoprecipitates were made using RL-1 or 
RL-2 and radioiodinated cell surface materials from HPB-ALL cells. These were 
analyzed on SDS-PAGE (Fig.  1). 
RL-1 precipitated a 67,000 mol wt protein from HPB-ALL cell lysate. Side by 
side  comparison  using  RL-1  and  monoclonal anti-Leu°l  antibody showed  that 
these  two  reagents  detected  the  same  molecular  weight  protein.  Sequential 
immunoprecipitation  resulted  in  the  removal  of the  same  molecule  by  both 
antibodies (data not shown). 
RL-2  precipitated a  single band  of 33,000  mol wt protein in a  reducing gel 
from  HPB-ALL cell lysate.  A  similar  33,000  mol  wt  protein  was  precipitated 
with  the anti-Leu-2a antibody.  Sequential  immunoprecipitations  demonstrated 
that RL-2 and anti-Leu-2a detected the same molecule (data not shown). Under 
nonreducing conditions, the 33,000 mol wt component was replaced by a specific 
band of 69,000 mol wt in addition to higher molecular weight material in both 
the  RL-2  and  anti-Leu-2a  immunoprecipitates.  Thus,  the  RL-2  antiserum  de- 
tected  the  Leu-2  antigen,  which  is  known  to  be  composed  of two  or  more 
disulfide-bonded subunits of 33,000 mol wt each (16). 
Spec~city a~d Sensitivity  of Leu ELISA.  Soluble Leu antigens were specifically 
absorbed  to the  monoclonal antibodies  attached  to a  plate and  these  antigens FUJIMOTO,  LEVY,  AND  LEVY  755 
FIGURE  |.  SDS-PAGE analysis under  reducing conditions of Leu-1  and  Leu-2  antigens 
precipitated from radioiodinated HPB-ALL cell lysate.  (A) normal rabbit serum (NRS), (B) 
monoclonal anti-HLA-DR L227,  (C)  monoclonal anti-Leu-1, (D)  RL-1,  (E)  RL-2,  and (F) 
monoclonal anti-Leu-2a. Leu-2 antigen was analyzed also under nonreducing conditions: (G) 
RL-2,  (/4)  anti-Leu-2a, (I)  NRS, and O  r)  L227.  The  monoclonal anti-HLA-DR framework 
(L227) is used as a control antibody in this experiment (35). 
were then detected by specific antisera (RL-1 or RL-2) or by another monoclonal 
antibody (detailed in Materials and Methods).  As a  source of Leu antigens,  cell 
lysates from a variety of cell lines known to vary in their Leu antigen expression 
were used (Fig. 2). 
In the Leu-1 assay, cell lysates from all the T  cell lines were reactive, whereas 
a  cell  lysate from  the  B  cell  line,  8866,  was inactive.  These  results  correlated 
very well with the cell surface expression of Leu-1 antigen. No signal was obtained 
when the inappropriate rabbit antiserum (i.e., anti-Leu-2) was used as a detector 
in  this  assay.  This  result  confirmed  the  specificity  of  the  rabbit  anti-Leu-1 
antiserum.  Moreover,  it  indicates  that  the  Leu-1  molecules  in  the  detergent 
lysate were dissociated rather than part of membrane fragments. 
In the  Leu-2 ELISA, only cell lysates from T  cell lines that expressed Leu-2 
antigen  on their cell surface were positive. Once again,  no signal was obtained 
when  the  inappropriate  rabbit  antiserum  (in  this  case anti-Leu-1)  was  used as 
detector.  The  Leu-2  signal  varied  among  the  Leu-2-positive  cell  lysates.  Cell 
lysates from  Leu-2 antigen-negative  cell lines and that  from a  B cell line  were 
completely negative. 
For the detection  of Leu-3 we used two monoclonal  antibodies,  anti-Leu-3a 
and anti-Leu-3b, which recognize different antigenic determinants  on the same 
molecule (2).  The avidin-biotin  reaction was used to amplify the antigen  signal. 
By using mouse monoclonal antibodies on both sides of the antigen there was no 756  SPONTANEOUS RELEASE OF LEU-2 (T8) FROM HUMAN T  CELLS 
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FIGURE 2.  Standard  curves obtained in each Leu  EL1SA with cell lysates  from HPB-ALL 
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Antigen signals obtained in each Leu ELISA with cell lysates  equivalent to 6.25 
cross-reactivity  of  the  detecting  reagents.  Fig.  2  shows  the  standard  curves 
obtained from various cell lines.  Of note are  the  cell lysates from  255.88  and 
Jurkat, which demonstrate the specificity of this Leu-3 ELISA. Cell line 255.88 
is a  hybridoma made between activated human  peripheral  blood T  cells and a 
drug-marked  variant of the Jurkat cell line.  Interestingly,  Leu-3 antigen,  which 
is not present  on  parent  cell Jurkat,  is expressed on  the  hybrid clone,  255.88 
(18). The ceil lysate from 255.88 showed the strongest Leu-3 signal among the 
Leu-3-positive cell lines tested whereas the cell lysate from the Jurkat parent was 
negative.  Cell  lysates from  other  Leu-3-positive cell  lines also showed various 
degrees of positive signals. Once again, the lysate from a B cell line was negative. 
Fig. 3 shows the Leu-1, -2, and -3 ELISA results for each of the cell lines listed 
in Table  I. All the B cell lysates were negative and the results from the T  cell FUJIMOTO,  LEVY,  AND  LEVY  757 
lysates were totally concordant with their surface phenotypes. The sensitivity of 
Leu ELISA assays is shown in Table II. In all three assays, antigen signals from 
as few as 5 x  103 cell equivalents could be reliably detected. 
Leu Antigen Activities in Culture Supernatant from Cell Lines.  To investigate the 
possibility of Leu antigen release from cells, supernatants of cultured cell lines 
were examined (Fig. 4).  The supernatants were collected when the cell density 
was "~ 106/ml; a time when cell viabilities remained >93%. All the supernatants 
were negative for Leu-1 and Leu-3. However, some of the supernatants from T 
cell lines gave positive results in the Leu-2 ELISA. Leu-2 antigen was found only 
in the supernatants from the cell lines that expressed Leu-2 antigen on the cell 
surface. The presence of Leu-2 antigen in the supernatant was unlikely to be the 
result of cell destruction during culture since neither Leu-1 nor Leu-3 was found 
in  the  same  supernatant.  Therefore,  the  existence  of Leu-2  antigen  in  the 
supernatants appeared to be the result of spontaneous release from cells. 
Time Course of  Leu-2 Accumulation in Culture Supernatant.  The kinetics of Leu- 
2 antigen release by cultured HPB-ALL cells is shown in Fig. 5. A comparison 
was made between cells cultured in the presence or absence of FCS. Cell numbers 
in culture with FCS increased progressively with viability remaining >92%. Cell 
numbers in  culture without  FCS  did  not increase beyond one doubling.  Cell 
TABLE  II 





Optical density reading with cell lysates from 
indicated number of cells* 
5x  10  3  0.16xlO s  P 
Leu-I  22  93.4 +  15.2  $  06.5 _+ 04.3  <  0.00050 
Leu-2  27  79.6 __. 09.9  10.7  _.+ 05.0  <  0.0005 
Leu-3  16  63.7 +_ 09.8  06.9 +  04.8  <  0.0005 
* Cell  numbers of HPB-ALL cells for  Leu-1  and  Leu-2  assays  and of 
255.88 cells for Leu-3 assay. 
* Mean optical density 405 nm readings + SEM (x 10-3). 
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FIGURE 5.  Time course of Leu-2 antigen appearance in supernatant. HPB-ALL cells were 
adjusted to 2.5 x  105/ml and cultured with or without FCS. (©) Cell numbers in culture; (O) 
Leu-2 ELISA signals obtained from 50 #1 of culture supernatant. Antigen amount is calculated 
as cell equivalents per milliliter. 
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FIGURE 6.  Purification of Leu-2 antigen from supernatant of HPB-ALL cells. Leu-2 antigen 
activity of culture supernatant was measured by ELISA before application on an anti-Leu-2a 
affinity column (O);  effluent fraction from the column (1"3); and fraction eluted with glycine 
HCI, pH 2.7 (O). 
viability without FCS remained >90% by day two but fell to 54% by day 3.  In 
the culture with  FCS,  Leu-2 activity in the supernatant  was found to correlate 
well  with  cell  numbers.  In  culture  without  FCS,  Leu-2  activity still  increased 
although  the cell number remained relatively constant.  From these results,  the 
following conclusions can be drawn (a) the appearance of Leu-2 in the superna- 
tant does not depend on the presence of FCS; (b) Leu-2 level in the supernatant 
correlates with the cell number in growing cultures;  (c) Leu-2 antigen accumu- 
lates in the supernatant  of very low density cuhure; and (d) the amount of Leu- 
2 antigen  accumulated in  the supernatant  can exceed that contained within  the 
cells by a factor of three. 
Put,cation  of Leu-2  Antige~  firm  HPB-ALL  Supernatant  with  an  Anti-Leu-2a 
Affi~it~, Colum,.  A  20-ml  sample  of culture  supernatant  from  HPB-ALL was 
applied  to an  anti-Leu-2a  affinity column.  After dialyzing  the  eluted  fraction 
against PBS and adjusting the volume, the Leu-2 ELISA was repeated. As shown 
in  Fig.  6,  the  Leu-2 activity in the supernatant  was completely absorbed by an 
anti-Leu-2 affinity column and was almost completely recovered from the column FUJIMOTO,  LEVY,  AND  LEVY  759 
by elution with 0.2 M glycine HCI, 0.5 M NaCI, pH 2.7 buffer. 
Leu-2 Amigen in the Supernatant Has Only One Leu-2a Determinant.  The Leu-2 
antigen has been shown to be composed of multiple polypeptide chains bound 
by disulfide bonds. To explore the molecular nature of the Leu-2 antigen in the 
supernatant we developed another ELISA which used the monoclonal anti-Leu- 
2a  antibody  on  both  sides of Leu-2  antigen  (repetitive determinant  ELISA). 
Instead of using RL-2  for the detection of Leu-2 antigen, we used biotinated 
anti-Leu-2a followed by HRP-avidin. The sensitivity of the repetitive determinant 
ELISA was % that of the original assay (Fig.  7A).  However, the Leu-2 antigen 
was readily detected in cell lysates by both assays.  This result confirms that Leu- 
2 antigen in cell extracts has at least two Leu-2a determinants. By contrast, the 
Leu-2  antigen  in  culture  supernatants  failed  to  give  a  positive  signal  in  the 
repetitive determinant assay (Fig. 7B). These results suggest that Leu-2 antigen 
in the supernatant had only one Leu-2a determinant per molecule. 
Released  Leu-2 Antigen is a Single Polypeptide  Chain.  Since the results obtained 
in  the  repetitive  determinant  Leu-2  assay  suggested  that  the  Leu-2  antigen 
present in the supernatant might be a single chain, we characterized the structure 
of the released Leu-2 antigen. The affinity-purified Leu-2 antigen from culture 
supernatant of HPB-ALL cells was radioiodinated and the radiolabeled antigen 
was immunoprecipitated and analyzed by SDS-PAGE. As shown in Fig. 8 C, the 
released  Leu-2  antigen  was  a  single  band  of 27,000  mol  wt  under reducing 
conditions that was smaller by 5,000 mol wt than the Leu-2 chain present on the 
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FIGURE 7.  Comparison of Leu-2 antigen signals obtained from cell lysate or culture super- 
natant  of HPB-ALL cells using  two different ELISA assays.  Closed symbols represent  the 
signals obtained by conventional ELISA using anti-Leu-2a and RL-2. Open symbols represent 
the signals obtained with a repetitive determinant Leu-2 ELISA that uses the same monoclonal 
anti-Leu-2a antibody on both sides of the antigen.  (A) Cell lysates;  (B) culture supernatants 
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FIGURE 8.  Leu-2 antigen was immunoprecipitated from either radioiodinated HPB-ALL cell 
lysate (A, B, E-H) or from  radioiodinated  Leu-2 antigen  purified from supernatant  of HPB- 
ALL  cells  (C,  D,  I,  and J)  and  was  analyzed  by  SDS-PAGE  under  reducing  (A-D) or 
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FIGURE 9.  Leu-2 antigen  ELISA with normal  human sera and sera from leukemia patients. 
Leu-2  antigen  amounts  are  expressed  as  HPB-ALL  cell  equivalents  per  milliliter.  Surface 
phenotypes of leukemia cells: T-ALL (cases  1 and 2), Leu-1 +, 2  ÷, 3  +, and 4+; T-ALL (case 3), 
Leu-1 ÷, 2-, 3-, and 4÷; B-CLL (cases  1 and 2), Leu-1 ÷, 2-, 3-, 4-, and surface IgM  ÷. 
conditions, the released  Leu-2 antigen (Fig. 81) showed exactly the same molec- 
ular weight  found under reducing conditions,  whereas the  Leu-2 antigen  from 
the cell  surface  moved to higher  molecular  weight positions (Fig.  8,  E  and F). 
Therefore,  it seems very likely  that Leu-2 antigen present  in the supernatant is 
a single polypeptide chain which has only one Leu-2a determinant. 
High Levels of Leu-2 A~tigen  in Serum of Patients with Leu-2 + Leukemia.  Normal 
sera  were  examined  for  the  presence  of Leu-2  antigen  and almost  all  of them 
were found to have a low but significant  level (Fig.  9).  Sera from five leukemia 
patients, which included T-ALL (three cases) and B-CLL (two), were also tested 
in  the  assay;  high  amounts  of Leu-2  activity  were  found  in  sera  from  Leu-2- 
positive  T-ALL  patients.  These  sera  were  also  checked  for  Leu-1  and  Leu-3 
antigen activity and they showed no significant activity (data not shown). 
Discussion 
In this report we describe  the development  of sensitive  ELISA assays for the 
detection  of human T  cell  antigens  in  soluble  form.  Leu-1  and  Leu-9  antigens FUJIMOTO,  LEVY, AND  LEVY  761 
were  detected  by  using  a  combination  of monoclonal  antibodies  and  newly 
prepared antisera.  RL-1 and  RL-2 were made in rabbits by immunization  with 
Leu antigens absorbed to monoclonal antibody affinity columns. The advantage 
of heterologous antisera  is their  reaction with multiple antigenic  determinants 
on an antigen molecule. On the other hand, monoclonal antibodies, which react 
with single antigenic  determinants,  can easily be purified and  used to prepare 
solid-phase affinity matrices. These respective advantages were exploited in the 
development of the Leu ELISA assays. 
For the detection of Leu-3  antigen,  two monoclonal  antibodies,  anti-Leu-3a 
and anti-Leu-3b, which recognize different determinations on the same molecule, 
were used (2). The specificity and avidity of the avidin-biotin reaction were used 
to strengthen this assay (21). The ELISA assays could detect antigen signals from 
as few as 5  ×  10  s cell equivalents of cells expressing those antigens (Table II). 
Assuming an antigen content on the order of ! 05 molecules per cell and molecular 
weights of 67,000,  70,000,  and 55,000 for Leu-1, -2, and -3, respectively (22), 
the ELISA assays have a sensitivity in the sub-ng range. 
With these Leu ELISA, we found the specific appearance of Leu-2 antigen in 
the supernatants  from Leu-2-positive T  cell lines. The presence of Leu-2 in the 
supernatant did not depend on FCS or on cell proliferation.  The Leu-2 antigen 
level in  the  supernatant  was found  to  correlate  with  cell  numbers  in  culture, 
although  in  the  absence  of FCS  where  cell  proliferation  was  minimized,  the 
antigen accumulated to an amount greater than that present in the existing cells. 
The Leu-2 molecule in the supernatant could be effectively purified with an anti- 
Leu-2a antibody affinity column. This technique will clearly be of value for the 
isolation and structural characterization  of the Leu-2 antigen. 
The  Leu-2, or T8, antigen  is considered to be the human  homologue of the 
mouse  Lyt-2,  Lyt-3  antigens  (16,  23,  24).  The  Leu-2  antigen  has  a  subunit 
structure of two or more disulfide-bonded polypeptide chains (16). These chains 
have mol wts of 32,000 and 43,000 when isolated from thymocytes. However, 
only a  32,000 mol wt chain was isolated on peripheral T  lymphocytes (16). The 
T5 and T8 antigens are apparently the same as the Leu-2 antigen (24, 25). Anti- 
T5  precipitated  a  76,000  mol  wt  glycoprotein  from  human  thymocytes and 
mitogen-stimulated  human  peripheral  T  lymphocytes. This molecule separated 
into 30,000 and  32,000  tool wt proteins under reducing  conditions (25).  Both 
anti-T5  and  anti-T8  precipitated  the  33,000  mol  wt protein  from  HPB-ALL 
cells under reducing conditions (24). The T5 and T8 determinants are apparently 
on different portions of the molecule.  In a functional study, anti-T8 was shown 
to have an inhibitory effect on cytotoxic T  lymphocyte (CTL), whereas anti-T5 
did not (24). Our rabbit antiserum RL-2 and anti-Leu-2a detected a single chain 
which had a mol wt of 33,000 from radioiodinated HPB-ALL cell lysates under 
reducing  conditions.  In  a  nonreducing  gel,  the  33,000  mol  wt chain  was  no 
longer detectable. Instead, 69,000 and higher mol wt forms were found. 
To  study the  molecular  nature  of Leu-2  antigen  released  from  T  cells,  we 
have developed another  Leu-2 assay which depends on the fact that  the intact 
Leu-2  molecule has  repeating  antigenic  determinants.  In  this  repetitive deter- 
minant assay, supernatants from T  cell lines were negative while cell lysates from 
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Leu-2 antigen in the supernatant had only one Leu-2a determinant,  whereas the 
Leu-2  antigen  from  cell  ]ysates had  at  least  two  Leu-2a  determinants.  These 
observations suggested  that  only a  single  chain  of Leu-2  antigen  was released 
into the supernatant.  To confirm  this  point,  we characterized  the structure  of 
the released Leu-2 antigen. The affinity-purified Leu-2 antigen from supernatant 
of HPB-ALL cells  was  radioiodinated,  immunoprecipitated,  and  analyzed  by 
SDS-PAGE. Since the released Leu-2 antigen  showed a single band under both 
reducing  and  nonreducing  conditions,  we  concluded  that  the  Leu-2  antigen 
present in the supernatant of HPB-ALL cells was a single polypeptide chain with 
only one Leu-2a determinant,  whereas the Leu-2 antigen present on HPB-ALL 
cell  surface  was  composed  of  identical  chains  and  had  at  least  two  Leu-2a 
determinants  per molecule.  More interestingly,  the released Leu-2 antigen  was 
a protein of 27,000 mol wt that was smaller than the Leu-2 antigen present on 
the cell surface. The mechanism  of Leu-2 release is not yet clear. There are at 
least  two  possible  mechanisms:  shedding  from  cell  surface  and  secretion  by 
exocytosis. We have not yet detected the Leu-2 antigen  in cell lysates from cell 
lines that have no detectable Leu-2 antigen on their cell surface. Thus, shedding 
of this antigen  may be one possible mechanism.  However, the possibility of the 
secretion cannot be excluded. More precise study, which includes analysis of cell 
lines or mutant cells that do not express Leu-2 antigen on cell surface, internal 
labeling, and pulse and chase experiments,  may resolve these questions. 
Is release of Leu-2 antigen  from cells a physiological phenomenon  or is it an 
artifact of in  vitro cell culture? To answer this question,  we examined  normal 
human sera and sera from leukemia patients for the presence of Leu-2 antigen. 
Normal human serum contained small amounts of Leu-2 antigen but when sera 
from  Leu-2  + patients were tested, high  amounts of Leu-2 antigen  were found. 
Interestingly, sera from a patient with Leu-2-negative T  cell leukemia and from 
patients with B-CLL had low, but significant, levels of Leu-2 antigen. 
In  mouse,  Lyt-2 antigen  has been thought  to be a  general  marker  for CTL 
and has been supposed to be involved in CTL function (26, 27). Recent studies 
have  suggested  that  Lyt-2  antigen  is  not  required  in  cytotoxic activity but  is 
responsible for the recognition of major histocompatibility complex (MHC) (28, 
29). In humans,  Leu-2, or T8, antigen  is thought to play a role similar to Lyt-2 
in cellular interaction.  Anti-Leu-2a antibody has shown to block proliferation of 
Leu-2 + T  cells in allogeneic mixed lymphocyte reaction (MLR) (7).  Anti-Leu-2a 
or anti-T8  also block the killing  of CTL generated  in allogeneic MLR (2,  24). 
Clonal analysis suggested that  T8 + CTL recognized class I  MHC molecules on 
the target cell but T8-T4 + CTL recognized class II MHC molecules (9,  10). 
T8 + or Leu-2 + T  cells have been shown to suppress immunoglobulin produc- 
tion by B cells induced by T4 ÷ or Leu-3 + T  cells (30-32).  Further,  production 
of helper factor by T4 + cells capable of inducing polyclonal activation of B cells 
was  found  to  be  suppressed  by T8 + cells  (33).  Although  Reinherz  et  al.  (24) 
reported that anti-T8 did not influence suppression ofimmunoglobulin secretion 
mediated  by T8  cells,  the  direct  participation  of T8  or  Leu-2  antigen  in  the 
suppressive function of T8+ or Leu-2+ cells remains unclear. Functional analysis 
using purified Leu-2 or T8 molecules may clarify these points and, in this regard, 
the  use of released  Leu-2  molecule may provide a  new approach  to study the FUJIMOTO, LEVY, AND  LEVY  763 
mechanism of cellular interaction. 
The  use of monoclonal  antibodies has  not been restricted  to the analysis of 
cellular function. Clinical trials are underway to explore the effects of monoclonal 
antibodies as therapeutic tools for the treatment of malignant  and immunoreg- 
ulatory diseases (11-15,  34). We have found that circulating Leu-1 antigen can 
be detected in  the  serum  of patients  after monoclonai  antibody infusion  (11). 
Such  release  of Leu°l  after  anti-Leu-1  antibody administration  is  not accom- 
panied by the release of Leu-2 or Leu-3 antigens. These results suggest that the 
release of cell surface antigen  after antibody treatment  is not the result of cell 
destruction  but  is  an  antigen-specific  phenomenon.  Further  analysis  will  be 
necessary to clarify the precise mechanism of antigen  release from cells in vivo, 
especially when the release of antigen  is induced by antibody. The fact that  in 
one  circumstance,  Leu-2,  there  is  basal  release  of antigen  into  the  serum  of 
leukemia  patients,  and  in  another  case,  Leu-1,  there  is  release  after  antibody 
administration,  underscores  the  importance  of  the  assays  reported  here  to 
monitor patients receiving therapy with antibodies and,  possibly, during chem- 
otherapy as well. 
Summary 
Sensitive enzyme-linked  immunosorbent  assays (ELISA) for the detection of 
human  T  cell  antigens  in  soluble form  have  been  developed.  The  assays use 
mouse monoclonal antibodies and specific anti-Leu sera prepared in rabbits by 
immunizing with Leu antigens absorbed to monoclonal antibody affinity columns. 
With these assays, Leu-1, -2, and -3 antigen  signals from extracts of as few as 5 
×  103 cells could be detected. When culture supernatants from various cell lines 
were tested,  Leu-2 antigen,  but not Leu-1  or Leu-3,  was found to be present. 
Leu-2 antigen was present only in supernatants  from T  cell lines that expressed 
Leu-2  on  their  cell  surface.  Leu-2  antigen  accumulated  progressively  in  the 
supernatant  of low  density  culture  and  its  presence  did  not  depend  on  cell 
proliferation  or on fetal calf serum in the culture medium.  The Leu-2 antigen 
in  the  supernatant  was  found  to have  only one  Leu-2a  determinant,  whereas 
Leu-2  antigen  from  cell  extracts  had  at  least  two  determinants.  The  Leu-2 
molecule was effectively purified from supernatant  with an anti-Leu-2a affinity 
column. The purified  Leu-2 antigen  from supernatant  of HPB-ALL cells was a 
single polypeptide chain  of 27,000  mol wt,  whereas  Leu-2 antigen  present  on 
HPB-ALL cell surface was composed of two or more identical polypeptide chains 
of 33,000 mol wt linked by disulfide bonds. Normal human  sera and sera from 
leukemia  patients  were also examined  for  the  presence  of the  Leu-2  antigen. 
Normal human sera contained low levels of Leu-2 antigen but sera from Leu-2- 
positive  leukemia  patients  had  high  levels.  These  results  indicate  that  Leu-2 
antigen is released from human T  cells under physiological conditions. 
We wish to thank Dr. Edgar Engleman for the use of the 255.88 cell line and Dr. Stanford 
Stewart and Dr. David Maloney for helpful discussions. 
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